uniQure N.V.

-0.07 (-0.49%)
Products, Regulatory

Uniqure Announces Completion Of Patient Enrollment In The First Two Cohorts Of Its Phase I/Ii Clinical Trial Of Amt-130 For The Treatment Of Huntington's Disease

Published: 03/21/2022 12:37 GMT
uniQure N.V. (QURE) - Uniqure Announces Completion of Patient Enrollment in the First Two Cohorts of Its Phase I/ii Clinical Trial of Amt-130 for the Treatment of Huntington’s Disease.
Uniqure NV - Look Forward to Providing a Clinical Update in Q2 of This Year From 12-month Interim Analysis of 10 Patients in First Cohort.
Uniqure NV - Remain on Track With Enrollment of Our European Open-label Clinical Trial of Amt-130.